Please use this identifier to cite or link to this item:
https://accedacris.ulpgc.es/handle/10553/52045
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pérez, Antonio | en_US |
dc.contributor.author | Wägner, Ana Maria | en_US |
dc.contributor.author | Carreras, Gemma | en_US |
dc.contributor.author | Giménez, Gabriel | en_US |
dc.contributor.author | Sánchez-Quesada, Jose Luis | en_US |
dc.contributor.author | Rigla, Mercedes | en_US |
dc.contributor.author | Gómez-Gerique, Juan Antonio | en_US |
dc.contributor.author | Pou, Jose Maria | en_US |
dc.contributor.author | De Leiva, Alberto | en_US |
dc.date.accessioned | 2018-11-25T16:59:02Z | - |
dc.date.available | 2018-11-25T16:59:02Z | - |
dc.date.issued | 2000 | en_US |
dc.identifier.issn | 0003-9926 | en_US |
dc.identifier.uri | https://accedacris.ulpgc.es/handle/10553/52045 | - |
dc.description.abstract | Background Data on the prevalence of dyslipidemia in type 1 diabetes mellitus are scarce and are based on total triglyceride and total cholesterol concentrations alone. Objective To assess the effect of glycemic optimization on the prevalence of dyslipidemia and low-density lipoprotein cholesterol (LDL-C) concentrations requiring intervention in patients with type 1 diabetes. Patients A total of 334 adults with type 1 diabetes and 803 nondiabetic control subjects. Methods Levels of glycosylated hemoglobin, total cholesterol, total triglyceride, high-density lipoprotein cholesterol (HDL-C), and LDL-C were assessed at baseline and after 3 to 6 months of intensive therapy with multiple insulin doses. Results Levels of LDL-C greater than 4.13 mmol/L (>160 mg/dL) and total triglyceride greater than 2.25 mmol/L (>200 mg/dL) and low HDL-C levels (<0.9 mmol/L [<35 mg/dL] in men or <1.1 mmol/L [<45 mg/dL] in women) were found in 16%, 5%, and 20% of patients and 13%, 6%, and 9% of controls, respectively (P<.001 for HDL-C). Diabetic women showed more hypercholesterolemia than nondiabetic women (15.6% vs 8.5%; P = .04). After glycemic optimization (mean ± SD glycosylated hemoglobin decrease, 2.2 ± 1.96 percentage points), the prevalence of LDL-C levels greater than 4.13 mmol/L (>160 mg/dL) became lower in diabetic men than in nondiabetic men (9.7% vs 17.5%; P = .04), but women showed frequencies of dyslipidemia similar to their nondiabetic counterparts. The proportion of patients with LDL-C concentrations requiring lifestyle (>2.6 mmol/L [>100 mg/dL]) or drug (>3.4 mmol/L [>130 mg/dL]) intervention decreased from 78% and 42% to 66% and 26%, respectively. Conclusions Low HDL-C is the most frequent dyslipidemic disorder in patients with poorly controlled insulin-treated type 1 diabetes, and a high proportion show LDL-C levels requiring intervention. Less favorable lipid profiles could explain the absence of sex protection in diabetic women. The improvement caused by glycemic optimization puts forward intensive therapy as the initial treatment of choice for dyslipidemia in poorly controlled type 1 diabetes. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Archives of internal medicine (1960) | en_US |
dc.source | Archives of Internal Medicine[ISSN 0003-9926],v. 160(18), p. 2756-2762 (Octubre 2000) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 3205 Medicina interna | en_US |
dc.subject | 320502 Endocrinología | en_US |
dc.subject.other | Dyslipidemia | en_US |
dc.subject.other | Diabetes mellitus | en_US |
dc.subject.other | Glycosylated hemoglobin | en_US |
dc.subject.other | Cholesterol | en_US |
dc.subject.other | Lipoprotein | en_US |
dc.title | Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: Effect of glycemic control | en_US |
dc.type | info:eu-repo/semantics/article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1001/archinte.160.18.2756 | en_US |
dc.identifier.scopus | 0034626386 | - |
dc.contributor.authorscopusid | 7402509742 | - |
dc.contributor.authorscopusid | 7401456520 | - |
dc.contributor.authorscopusid | 6603602740 | - |
dc.contributor.authorscopusid | 23970533700 | - |
dc.contributor.authorscopusid | 6603877734 | - |
dc.contributor.authorscopusid | 6603627533 | - |
dc.contributor.authorscopusid | 7003411647 | - |
dc.contributor.authorscopusid | 14322294200 | - |
dc.contributor.authorscopusid | 7005846734 | - |
dc.description.lastpage | 2762 | en_US |
dc.identifier.issue | 18 | - |
dc.description.firstpage | 2756 | en_US |
dc.relation.volume | 160 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.description.numberofpages | 7 | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Octubre 2000 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.jcr | 6,055 | - |
dc.description.jcrq | Q1 | - |
item.fulltext | Sin texto completo | - |
item.grantfulltext | none | - |
crisitem.author.dept | GIR IUIBS: Diabetes y endocrinología aplicada | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0002-7663-9308 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Wägner, Anna Maria Claudia | - |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
63
checked on Mar 30, 2025
WEB OF SCIENCETM
Citations
58
checked on Mar 30, 2025
Page view(s)
92
checked on Jan 25, 2025
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.